TRION Pharma GmbH Patent applications |
Patent application number | Title | Published |
20140369985 | REMOVAL OF TUMOR CELLS FROM INTRAOPERATIVE AUTOLOGOUS BLOOD SALVAGE - The invention relates to a method performed ex vivo for removal of tumor cells from intraoperatively collected blood salvage, to antibodies and scaffold proteins which mimic antibodies for use in said ex vivo method, to the use of said ex vivo method for removal of tumor cells from intraoperatively collected blood salvage followed by reintroducing the so obtained purified blood salvage or of concentrates of erythrocytes purified by said method to a patient from whom said intra-operatively collected blood was obtained, as well as to blood salvage or a concentrate of erythrocytes, both obtainable by said method for reinfusion to said patient. | 12-18-2014 |
20130095106 | USE OF TRIFUNCTIONAL BISPECIFIC AND TRISPECIFIC ANTIBODIES FOR THE TREATMENT OF MALIGNANT ASCITES - The invention describes the use of a pharmaceutical preparation containing a trifunctional bispecific and/or trispecific having the following properties:
| 04-18-2013 |
20120095192 | USE OF TRIFUNCTIONAL BISPECIFIC ANTIBODIES FOR THE TREATMENT OF TUMORS ASSOCIATED WITH THE CD133+/EPCAM+ CANCER STEM CELLS - Use of a trifunctional bispecific antibody having the following properties of a) binding to a T cell; b) binding to EpCAM as tumor-associated antigen on a tumor cell wherein the tumor cell additionally carries the membrane bound glycoprotein CD 133; c) binding by its Fc portion to Fc receptor-positive cells for the preparation of a pharmaceutical composition for the destruction of cancer stem cells carrying the tumor-associated antigen EpCAM and the membrane bound glycoprotein CD 133 in a population of patients suffering from a tumor. | 04-19-2012 |
20100322933 | INTRAOPERATIVE TRIFUNCTIONAL ANTIBODY APPLICATION FOR PROPHYLAXIS OF INTRAPERITONEAL TUMOR CELL DISSEMINATION - The invention describes the use of trifunctional bispecific and trispecific antibodies for destroying tumor cells which e.g. are disseminated intraperitoneally due to a surgical intervention, wherein the antibody is administered intraoperatively, preferably directly locally into the abdominal cavity. | 12-23-2010 |